{
  "id": 12421417,
  "title": "Needham reiterates Buy on HubSpot stock after workforce reduction",
  "url": "https://urgent.news/2026/10/06/needham-reiterates-buy-on-hubspot-stock-after-workforce-reduction",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-06T16:24:50.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/needham-reiterates-buy-on-hubspot-stock-after-workforce-reduction-93CH-4934994"
  },
  "original_language": "en",
  "account": "Needham has reaffirmed its Buy rating and $300 price target for HubSpot Inc (HUBS) following the company's announcement of a 7% workforce reduction. The stock, currently trading at $219.97, has seen a 52% decline over the past year but has recovered 11.6% in the recent week. This workforce reduction, effective before market open, is part of a strategic realignment to accelerate innovation and sharpen the organization. Needham expressed admiration for HubSpot's product updates at Unbound 2026, highlighting the acceleration and magnitude of change in marketing software over the past two decades. The firm anticipates HubSpot to gain market share in the next industry growth cycle, expected to resume in late 2027 or early 2028. Needham has left its fiscal year 2026 and third-quarter guidance unchanged, anticipating further margin improvements. InvestingPro analysis suggests the stock is currently undervalued, listing it among opportunities on its most undervalued stocks list. HubSpot boasts impressive gross profit margins of 83% and possesses more cash than debt. The restructuring charges, encompassing severance and transition costs, are projected to range between $65 million and $75 million, primarily occurring in the fourth quarter. Various analyst firms have reacted differently to these developments, with Canaccord and RBC Capital issuing Buy ratings with a $300 price target, while Stifel and William Blair maintained Hold and Market Perform ratings respectively, reflecting more cautious optimism.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Stifel reiterates Kamada stock Buy rating on biosimilar expansion",
        "url": "https://urgent.news/2026/10/06/stifel-reiterates-kamada-stock-buy-rating-on-biosimilar-expansion",
        "published": "2026-10-06T15:02:52.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}